## Ivana Maida

## List of Publications by Citations

Source: https://exaly.com/author-pdf/9524974/ivana-maida-publications-by-citations.pdf

Version: 2024-04-10

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

59 papers 1,495 citations 22 h-index g-index

60 1,726 4 3.71 ext. papers ext. citations avg, IF L-index

#	Paper	IF	Citations
59	Hepatotoxicity of antiretroviral drugs is reduced after successful treatment of chronic hepatitis C in HIV-infected patients. <i>Journal of Infectious Diseases</i> , <b>2007</b> , 196, 670-6	7	127
58	Severe liver disease associated with prolonged exposure to antiretroviral drugs. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , <b>2006</b> , 42, 177-82	3.1	126
57	Noncirrhotic portal hypertension in HIV-infected patients: unique clinical and pathological findings. <i>Aids</i> , <b>2010</b> , 24, 1171-6	3.5	70
56	Rickettsia monacensis as cause of Mediterranean spotted fever-like illness, Italy. <i>Emerging Infectious Diseases</i> , <b>2012</b> , 18, 702-4	10.2	68
55	Kaposi's sarcoma herpes virus and Kaposi's sarcoma in the elderly populations of 3 Mediterranean islands. <i>International Journal of Cancer</i> , <b>2001</b> , 91, 588-91	7.5	63
54	Paradoxical CD4+ T-cell decline in HIV-infected patients with complete virus suppression taking tenofovir and didanosine. <i>Aids</i> , <b>2005</b> , 19, 569-75	3.5	62
53	Episodes of low-level viral rebound in HIV-infected patients on antiretroviral therapy: frequency, predictors and outcome. <i>Journal of Antimicrobial Chemotherapy</i> , <b>2008</b> , 61, 699-704	5.1	61
52	Predictors of virological response to atazanavir in protease inhibitor-experienced patients. <i>HIV Clinical Trials</i> , <b>2004</b> , 5, 201-5		61
51	Modulation by alpha- and gamma-tocopherol and oxidized low-density lipoprotein of apoptotic signaling in human coronary smooth muscle cells. <i>Biochemical Pharmacology</i> , <b>2000</b> , 59, 1477-87	6	56
50	Antiretroviral-Associated Portal Hypertension: A New Clinical Condition? Prevalence, Predictors and Outcome. <i>Antiviral Therapy</i> , <b>2008</b> , 13, 103-108	1.6	56
49	Activation of MSRV-type endogenous retroviruses during infectious mononucleosis and Epstein-Barr virus latency: the missing link with multiple sclerosis?. <i>PLoS ONE</i> , <b>2013</b> , 8, e78474	3.7	53
48	Low Response to Pegylated Interferon plus Ribavirin in HIV-Infected Patients with Chronic Hepatitis C Treated with Abacavir. <i>Antiviral Therapy</i> , <b>2008</b> , 13, 429-438	1.6	46
47	Serum homocysteine levels are increased in women with gestational diabetes mellitus. <i>Metabolism:</i> Clinical and Experimental, <b>2003</b> , 52, 720-3	12.7	45
46	Hepatic safety profile of raltegravir in HIV-infected patients with chronic hepatitis C. <i>Journal of Antimicrobial Chemotherapy</i> , <b>2010</b> , 65, 543-7	5.1	43
45	Does counseling increase sustained benefit of HAART among prison inmates after release to the community?. <i>Clinical Infectious Diseases</i> , <b>2005</b> , 40, 321-2; author reply 322-3	11.6	41
44	Sexual transmission is associated with spontaneous HCV clearance in HIV-infected patients. <i>Journal of Hepatology</i> , <b>2008</b> , 49, 323-8	13.4	36
43	Use of Pegylated Interferons is Associated with An Increased Incidence of Infections during Combination Treatment of Chronic Hepatitis C: A Side Effect of Pegylation?. <i>Antiviral Therapy</i> , <b>2004</b> , 9, 627-630	1.6	35

## (2014-2008)

42	Switch from ritonavir-boosted to unboosted atazanavir guided by therapeutic drug monitoring. <i>AIDS Research and Human Retroviruses</i> , <b>2008</b> , 24, 821-5	1.6	31
41	Simplification from protease inhibitors to once- or twice-daily raltegravir: the ODIS trial. <i>HIV Clinical Trials</i> , <b>2010</b> , 11, 197-204		28
40	Predictors of infection, symptoms development, and mortality in people with SARS-CoV-2 living in retirement nursing homes. <i>PLoS ONE</i> , <b>2021</b> , 16, e0248009	3.7	28
39	Frequent NS5A and multiclass resistance in almost all HCV genotypes at DAA failures: What are the chances for second-line regimens?. <i>Journal of Hepatology</i> , <b>2018</b> , 68, 597-600	13.4	23
38	Liver enzyme elevation in hepatitis C virus (HCV)-HIV-coinfected patients prior to and after initiating HAART: role of HCV genotypes. <i>AIDS Research and Human Retroviruses</i> , <b>2006</b> , 22, 139-43	1.6	23
37	Characteristics and prospects for hepatitis C therapy of an HIV-HCV coinfected population followed at a reference HIV center. <i>HIV Clinical Trials</i> , <b>2005</b> , 6, 329-36		22
36	Liver fibrosis in HIV-infected patients with chronic hepatitis B extensively exposed to antiretroviral therapy with anti-HBV activity. <i>HIV Clinical Trials</i> , <b>2006</b> , 7, 246-50		21
35	Hepatitis C Virus-Rna Clearance in HIV-Coinfected Patients with Chronic Hepatitis C Treated with Pegylated Interferon plus Ribavirin. <i>Antiviral Therapy</i> , <b>2004</b> , 9, 505-509	1.6	21
34	Hepatitis C virus coinfection does not affect CD4 restoration in HIV-infected patients after initiation of antiretroviral therapy. <i>AIDS Research and Human Retroviruses</i> , <b>2008</b> , 24, 935-40	1.6	20
33	Antiretroviral-associated portal hypertension: a new clinical condition? Prevalence, predictors and outcome. <i>Antiviral Therapy</i> , <b>2008</b> , 13, 103-7	1.6	20
32	Higher risk of hyperglycemia in HIV-infected patients treated with didanosine plus tenofovir. <i>AIDS Research and Human Retroviruses</i> , <b>2006</b> , 22, 333-7	1.6	19
31	Liver fibrosis stage and HCV genotype distribution in HIV-HCV coinfected patients with persistently normal transaminases. <i>AIDS Research and Human Retroviruses</i> , <b>2007</b> , 23, 801-4	1.6	17
30	Autoimmune hepatitis induced by pegylated interferon in an HIV-infected patient with chronic hepatitis C. <i>Journal of Antimicrobial Chemotherapy</i> , <b>2008</b> , 62, 1470-2	5.1	16
29	Ombitasvir, paritaprevir, and ritonavir, with or without dasabuvir, plus ribavirin for patients with hepatitis C virus genotype 1 or 4 infection with cirrhosis (ABACUS): a prospective observational study. <i>The Lancet Gastroenterology and Hepatology</i> , <b>2017</b> , 2, 427-434	18.8	13
28	Predictors of Hepatitis C Treatment Failure After Using Direct-Acting Antivirals in People Living With Human Immunodeficiency Virus. <i>Open Forum Infectious Diseases</i> , <b>2019</b> , 6, ofz070	1	12
27	Triple combination therapy for hepatitis C with telaprevir exhibits greater early antiviral activity than with boceprevir. <i>Antiviral Therapy</i> , <b>2013</b> , 18, 709-15	1.6	12
26	Upper gastrointestinal bleeding may unmask didanosine-associated portal hepatopathy in HIV/HCV co-infected patients. <i>HIV Clinical Trials</i> , <b>2008</b> , 9, 440-4		12
25	Mucocutaneous leishmaniasis as presentation of HIV infection in Sardinia, insular Italy. <i>Parasitology International</i> , <b>2014</b> , 63, 35-6	2.1	11

24	New paradigms in the management of HIV and hepatitis C virus coinfection. <i>Current Opinion in Infectious Diseases</i> , <b>2005</b> , 18, 550-60	5.4	11
23	Rate of virologic failure and selection of drug resistance mutations using different triple nucleos(t)ide analogue combinations in HIV-infected patients. <i>AIDS Research and Human Retroviruses</i> , <b>2006</b> , 22, 1231-5	1.6	10
22	Liver transplantation in HIV-HCV coinfected candidates: what is the most appropriate time for evaluation?. <i>AIDS Research and Human Retroviruses</i> , <b>2005</b> , 21, 599-601	1.6	10
21	Hepatitis C viremia in HIV/HCV-coinfected patients: lower levels in presence of chronic hepatitis B. <i>HIV Clinical Trials</i> , <b>2005</b> , 6, 103-6		7
20	Failure of hepatitis C therapy in HIV-coinfected drug users is not due to a shift in hepatitis C virus genotype. <i>Journal of Infectious Diseases</i> , <b>2005</b> , 192, 1245-8	7	7
19	First HAART in HIV-infected patients with high viral load: value of HIV RNA levels at 12 weeks to predict virologic outcome. <i>Journal of the International Association of Providers of AIDS Care</i> , <b>2009</b> , 8, 314	-7	6
18	DNMT1 modulation in chronic hepatitis B patients and hypothetic influence on mitochondrial DNA methylation status during long-term nucleo(t)side analogs therapy. <i>Journal of Medical Virology</i> , <b>2017</b> , 89, 1208-1214	19.7	5
17	OPERA: use of pegylated interferon plus ribavirin for treating HCV-HIV coinfection in interferon-naive patients. <i>Antiviral Therapy</i> , <b>2014</b> , 19, 735-45	1.6	5
16	Distinct Hepatitis C virus Kinetics in HIV-Infected Patients Treated with Ribavirin plus Either Pegylated Interferon 🛭 a or 🖺 b. <i>Antiviral Therapy</i> , <b>2008</b> , 13, 511-517	1.6	5
15	Very late HCV relapse following triple therapy for hepatitis C. <i>Antiviral Therapy</i> , <b>2014</b> , 19, 723-4	1.6	4
14	Virological rather than host factors are associated with transaminase levels among HIV/HCV-coinfected patients. <i>Journal of the International Association of Providers of AIDS Care</i> , <b>2010</b> , 9, 15-9		4
13	Ebola virus disease: Case management in the Institute of Infectious Diseases, University Hospital of Sassari, Sardinia, Italy. <i>Journal of Infection in Developing Countries</i> , <b>2016</b> , 10, 537-43	2.3	4
12	Hepatic peroxisome proliferator-activated receptor and EmRNA expression in HCV-infected adults is decreased by HIV co-infection and is also affected by ethnicity. <i>Clinics</i> , <b>2015</b> , 70, 790-6	2.3	4
11	The PaO2/FiO2 ratio on admission is independently associated with prolonged hospitalization in COVID-19 patients. <i>Journal of Infection in Developing Countries</i> , <b>2021</b> , 15, 353-359	2.3	4
10	Mood Reactive Disorders among COVID-19 Inpatients: Experience from a Monocentric Cohort. <i>Medical Principles and Practice</i> , <b>2021</b> , 30, 550-556	2.1	3
9	Emerging Clinical Features of COVID-19 Related Pancreatitis: Case Reports and Review of the Literature <i>Frontiers in Medicine</i> , <b>2021</b> , 8, 779118	4.9	2
8	Safety and Efficacy of Direct-Acting Antivirals in Transfusion-Dependent Thalassemic Patients with Chronic Hepatitis C. <i>Hepatitis Monthly</i> , <b>2018</b> , 18,	1.8	2
7	Cytopenias during treatment of HIV-HCV-coinfection with pegylated interferon and ribavirin: safety analysis of the OPERA study. <i>Antiviral Therapy</i> , <b>2015</b> , 20, 39-48	1.6	1

## LIST OF PUBLICATIONS

6	Complications in treating chronic hepatitis B in patients with HIV. <i>Expert Opinion on Pharmacotherapy</i> , <b>2005</b> , 6, 2831-42	4	1
5	Outbreak of acute hepatitis A associated with men who have sex with men (MSM) in North Sardinia 2017-2018. <i>Journal of Infection in Developing Countries</i> , <b>2020</b> , 14, 1065-1070	2.3	1
4	Effectiveness of Vitamin D Supplements among Patients Hospitalized for COVID-19: Results from a Monocentric Matched-Cohort Study. <i>Healthcare (Switzerland)</i> , <b>2022</b> , 10, 956	3.4	1
3	Hepatitis C Treatment Outcomes in Persons With HIV and Decompensated Cirrhosis Using a Collaborative Multidisciplinary HIV-Centered Approach. <i>Journal of the International Association of Providers of AIDS Care</i> , <b>2021</b> , 20, 23259582211024771	1.7	О
2	Effect of aging, glucose level, and HIV viral load on response to treatment with pegylated interferon plus ribavirin in HIV/HCV co-infected women. <i>Journal of Womenm Health</i> , <b>2015</b> , 24, 159-64	3	
1	The Bayesian reconstruction and the evolutionary history of Salivirus type 1 and type 2: the worldwide spreading. <i>Journal of Infection in Developing Countries</i> , <b>2021</b> , 15, 280-288	2.3	